PMID- 11454669
OWN - NLM
STAT- MEDLINE
DCOM- 20010802
LR  - 20220330
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 61
IP  - 14
DP  - 2001 Jul 15
TI  - Frequent loss of estrogen receptor-beta expression in prostate cancer.
PG  - 5331-5
AB  - The role of estrogen and its receptors in the etiology and progression of 
      prostate cancer (PC) is poorly understood. In normal and malignant human 
      prostate, estrogen receptor-alpha is expressed only in the stroma, whereas 
      estrogen receptor-beta (ERbeta) is present in both normal stroma and epithelium. 
      Because loss of ERbeta expression is associated with prostate hyperplasia in 
      ERbeta-null mice, this study determined patterns of ERbeta expression in normal, 
      hyperplastic, and malignant human prostate and associations with clinical 
      outcome. Five normal prostates from organ donors and 159 radical prostatectomy 
      specimens from patients with clinically localized PC were assessed for ERbeta 
      expression using immunohistochemistry. ERbeta-positivity was defined as > or =5% 
      of cells demonstrating nuclear immunoreactivity. All of the five normal prostates 
      showed strong ERbeta-nuclear staining in >95% of the epithelium and 35% of the 
      stromal cells. The number of ERbeta-positive cases declined to 24.2% (38/157) in 
      hyperplasia adjacent to carcinoma and 11.3% (18/159) in PCs. ERbeta-positivity 
      was related to decreased relapse-free survival (log-rank P = 0.04). Thus, loss of 
      ERbeta expression is associated with progression from normal prostate epithelium 
      to PC, whereas those cancers that retained ERbeta expression were associated with 
      a higher rate of recurrence. These data identify the need to further investigate 
      the potential role of ERbeta in the regulation of prostate epithelial cell 
      proliferation and the functional consequences of decreased ERbeta expression in 
      the evolution of PC.
FAU - Horvath, L G
AU  - Horvath LG
AD  - Cancer Research Program, Garvan Institute of Medical Research, St. Vincent's 
      Hospital, Darlinghurst, Sydney, NSW 2010, Australia.
FAU - Henshall, S M
AU  - Henshall SM
FAU - Lee, C S
AU  - Lee CS
FAU - Head, D R
AU  - Head DR
FAU - Quinn, D I
AU  - Quinn DI
FAU - Makela, S
AU  - Makela S
FAU - Delprado, W
AU  - Delprado W
FAU - Golovsky, D
AU  - Golovsky D
FAU - Brenner, P C
AU  - Brenner PC
FAU - O'Neill, G
AU  - O'Neill G
FAU - Kooner, R
AU  - Kooner R
FAU - Stricker, P D
AU  - Stricker PD
FAU - Grygiel, J J
AU  - Grygiel JJ
FAU - Gustafsson, J A
AU  - Gustafsson JA
FAU - Sutherland, R L
AU  - Sutherland RL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Estrogen Receptor alpha)
RN  - 0 (Estrogen Receptor beta)
RN  - 0 (Receptors, Estrogen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Disease-Free Survival
MH  - Estrogen Receptor alpha
MH  - Estrogen Receptor beta
MH  - Humans
MH  - Hyperplasia/metabolism/pathology
MH  - Immunohistochemistry
MH  - Male
MH  - Middle Aged
MH  - Prostate/chemistry/pathology
MH  - Prostatic Neoplasms/metabolism/*pathology
MH  - Receptors, Estrogen/*biosynthesis
EDAT- 2001/07/17 10:00
MHDA- 2001/08/03 10:01
CRDT- 2001/07/17 10:00
PHST- 2001/07/17 10:00 [pubmed]
PHST- 2001/08/03 10:01 [medline]
PHST- 2001/07/17 10:00 [entrez]
PST - ppublish
SO  - Cancer Res. 2001 Jul 15;61(14):5331-5.